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Abstract 
Jeremy Martinson, DPhil 
Infection Prevention Measures to Reduce External Ventricular Device-Related Surgical 
Meningitis and Ventriculitis 
Saniya Sandeep Sabnis, MPH 
University of Pittsburgh, 2019 
Abstract 
Introduction: Healthcare-associated infections (HAIs) are serious public health problems 
with significant morbidity and mortality. The reduction of intra-cranial pressure using external 
ventricular drains (EVDs) is a life saving measure. Unfortunately, infection is a major 
complication of this procedure. Therefore, reducing surgical meningitis and ventriculitis, or EVD-
related infection, is an important goal for healthcare infection prevention teams. 
Methods: This is a single center study performed at an academic medical center reviewing 
all EVD-related infections between January 2014 and October 2018. This is a pre- and post-study 
comparing the rates of meningitis and ventriculitis after EVD placement before and after 
application of infection prevention. The patients were selected using procedure ICD codes via 
electronic medical records (EMR). A confirmed infection was defined as a positive 
microbiological culture of the cerebrospinal fluid (CSF); a possible infection was defined as a high 
white blood cell count (>100 cells/ ml) and/ or a low glucose count (<40 mg/dl) in CSF. 
Results: During the study period, there were 106 procedures performed with 85 before and 
20 after the prevention. Infection occurred in 44 with 7 confirmed and 37 possible infections. There 
were 36 infections before and 8 infections after application of the infection prevention bundle. The 
v 
number of EVD days, EVD placement procedure (bedside vs. operation room), and CSF specimen 
source (EVD bag vs. buretrol) were associated with increased risk of infection. 
Conclusion: An EVD-related infection is a serious life-threatening HAI. Multiple risk 
factors were identified in this study including duration of EVD, EVD placement procedure, and 
CSF specimen source. The application of an effective evidence-based infection prevention bundle 
to reduce EVD-related surgical meningitis and ventriculitis is an essential intervention. 
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1.0 Background 
1.1 Hospital Associated Infections 
Healthcare-associated infections (HAIs) are a serious growing health concern on a global 
level; they increase morbidity and mortality of the patients, often reducing quality of life, and they 
usually elicit an economic burden on the hospital administration and healthcare workers, insurance 
companies, and patient, as well. The Centers for Disease Control and Prevention’s (CDC) Division 
of Healthcare Quality Promotion (DHQP) utilizes the National Healthcare Safety Network 
(NHSN) for passive HAI surveillance. Hospitals from all 50 states, Washington, D.C., and Puerto 
Rico all report HAIs to the NHSN. NHSN’s estimates for annual HAIs are as high as 1.7 million 
in all healthcare settings (Magill, et al., 2014). In the most recent multi-state study published by 
the CDC which spanned across 183 acute care hospitals, approximately 4% of patients out of over 
11,000 contracted at least 1 HAI. These numbers when applied to the national population indicate 
that on any day, 1 in 25 inpatients in acute care hospitals develop at least 1 HAI (Magill, et al., 
2014). The most recent NHSN numbers show that nearly 150,000 HAIs happened in acute care 
hospitals in 2017. When inpatient rehabilitation facilities, long-term acute care hospitals, and other 
healthcare facilities are taken into account, this number increases significantly, creating a 
significant burden on the healthcare system. Deaths associated with HAIs are nearly as high as 
100,000 per year (Klevens, et al., 2007). The massive amounts of HAIs that occur nationally cause 
a serious burden on the U.S. healthcare system that can be in the billions of dollars range. The 
CDC published numbers indicating that the annual direct medical costs of HAIs range between 
$28.4 billion to $45 billion (Scott, 2009). Surveillance can help to reduce HAIs by monitoring 
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infection trends and providing warnings for early outbreaks; by providing benchmarking to 
encourage healthcare workers to collaborate and perform surveillance and to increase their 
compliance to infection control standards; and by pinpointing potential risk factors associated with 
HAIs (Li, et al., 2017). By understanding and analyzing HAI data and implementing infection 
control interventions, savings resulting from stopping preventable infections can save between 
$5.7 billion to $31.5 billion annually (Scott, 2009). Additionally, the implementation of the 
Hospital-Acquired Conditions (HACs) Initiative in 2008 was a payment reform from the Centers 
for Medicare and Medicaid Services, which attempted to incentivize healthcare facilities into 
reducing HAIs (Waters, et al., 2015). The HACs Initiative stated that hospitals could no longer 
claim a high-level severity diagnosis to recoup costs for treating a patient who developed one of 
the eight never events, which include catheter-associated urinary tract infections and central line-
associated bloodstream infections (Waters, et al., 2015). This initiative further highlights the 
necessity for hospitals to want to decrease the incidence of HAIs amongst their patients. 
1.1.1  Types of HAIs 
HAIs are device-related infections, which include central line-associated bloodstream 
infections (CLABSI), catheter-associated urinary tract infections (CAUTI), and ventilator-
associated pneumonia (VAP) (Centers for Disease Control and Prevention, 2010) (Centers for 
Disease Control and Prevention, 2015) (Centers for Disease Control and Prevention, 2010). 
Surgical site infections (SSIs) are device-related infections that stem from EVD-related infections, 
implant-related infections that originate from prosthetic joint infections, or simply open wound 
infections that are introduced into the body through the locations where surgery took place 
(Centers for Disease Control and Prevention, 2010). These infections can be superficial on the skin 
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only or can be deeper and infect soft tissues, organs, implanted devices and material, and even 
bones. Nationally, the CDC uses surveillance data from the NHSN and the Emerging Infections 
Program Healthcare-Associated Infections – Community Interface (EIP HAIC) to track trends in 
incidence and prevalence on a state-wide basis (Centers for Disease Prevention and Control, 2018). 
Pneumonia and surgical site infections are the most common HAIs with an annually estimated 
prevalence of 24.3% each (Magill, et al., 2014). Gastrointestinal infections, urinary tract infections, 
and bloodstream infections are also frequently seen and estimated to have prevalence at 19.0%, 
14.4%, and 11.1%, respectively (Magill, et al., 2014). This study shows that device-associated 
infections only cause a quarter of the HAIs, whereas half of the HAIs are not caused by devices or 
operative procedures (Magill, et al., 2014). The importance of the study highlights necessity of 
refocusing public health initiatives from current efforts on device-associated infections only to 
include other more pressing infection causes. NHSN’s published numbers from 2017 indicate that 
there were 21,173 CLABSI, 24,865 CAUTI, 24,491 VAE, 20,625 SSI (Centers for Disease Control 
and Prevention, 2017). The predicted number of infections which are believed to have existed are 
25,996, 28,242, 25,731, and 21,967 for CLABSI, CAUTI, VAE, and SSI respectively (Centers for 
Disease Control and Prevention, 2017). According to the CDC, economically, this translates to 
$3.22 to $10.07 billion for SSI, $0.59-$2.68 billion for CLABSI, $0.78 to $1.50 billion for VAP, 
and $0.34 to $0.45 billion for CAUTI (Scott, 2009). A more recent meta-analysis on the impact of 
HAIs on the U.S. health system, specifically for adult inpatients at acute care hospitals, estimates 
that the incidence of SSIs are 1.98 per 100, CLABSIs are 1.27 per 100, CAUTIs are 1.87 per 100, 
and VAEs are 1.33 per 100, resulting in a total HAI incidence of 440,916 patients (Zimlichman, 
et al., 2013). This study then went on to conclude that the total attributable financial impacts of 
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HAIs at acute care hospitals to be $3 to $3.6 billion for SSIs, $1.25 to $2.64 billion for CLABSIs, 
$0.19 to $0.37 billion for CAUTIs, and $2.8 to $3.41 billion for VAEs (Zimlichman, et al., 2013). 
The NHSN uses standardized infection ration (SIR) as a summary statistic to track the 
spread of HAIs and the success of HAI prevention programs. SIR is a ratio of the number of 
observed infections over the number of predicted infections for that time period. The SIR helps to 
determine the change in HAIs from year to year. The SIRs for 2017 were 0.814 for CLABSI, 0.880 
for CAUTI, and 0.952 for VAE. The national data for acute care hospitals in 2017 when compared 
to the national baseline for acute care hospitals in 2016 indicate a 19% decrease in CLABSI, 12% 
decrease in CAUTI, a 5% decrease in VAP, an 11% decrease in SSIs related to abdominal 
hysterectomies, and a 9% decrease in SSIs related to colon surgery. All these decreases in 
infections were significant except the two SSI related results. Specifically, Pennsylvania data for 
acute care hospitals in 2017 when compared to the national baseline for acute care hospitals in 
2017 had a 21% decrease in CLABSI, a 15% decrease in CAUTI, a 7% decrease in VAP, no 
change in the incidence SSIs related to abdominal hysterectomies, and a 19% decrease in SSIs 
related to colon surgeries. Events related to CLABSI and CAUTI and were significantly lower in 
2017 when compared to Pennsylvania’s results in 2016. The rest showed no significant difference 
when comparing Pennsylvania results in 2016 to 2017. 
1.2 Neurosurgery HAIs 
Neurosurgery-associated HAIs are an important area that requires additional focus and 
research because of the severity of associated infections. ICUs generally have an increased rate of 
HAIs because of the severity of the medical condition of the patient or procedure, the increased 
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length of stay, and the frequent use of invasive medical devices; in fact, HAI incidence can reach 
as high as 30%, compared to the average of 1 in 25 patients (Abulhasan, et al., 2018). Based on 
the studies that are done, the incidence, prevalence, and economic burden of HAIs vary greatly 
depending on a multitude of factors, including but not limited to database used, infection 
prevention policies, and procedure- and patient-related aspects (DeAngelis, Murthy, Beyersmann, 
& Harbarth, 2010). Often times the only costs taken into account are direct costs, both fixed and 
variable, (e.g., utilities, equipment, medications, treatments and procedures, testing, and supplies) 
because indirect costs (e.g., lost wages, mortality and morbidity, pain and suffering) are nearly 
impossible to calculate (Scott, 2009). The types of study can also lead to vast differences in results. 
For example, a comparative cohort studies can lead to the rise of biases by not taking into account 
variables that could influence the cost (DeAngelis, Murthy, Beyersmann, & Harbarth, 2010). 
Taking these studies’ possible shortcomings and cause for variations into account, the 
chances of contracting HAIs in neurosurgical intensive care units can range between 5.9% to 
21.7% (Kupronis, Edwards, Horan, Richards, & Tokars, 2004) (Dasenbrock, et al., 2016) (Celik, 
2004) (Orsi, et al., 2006). These included all four classifications of HAIs, (i.e., CLABSI, CAUTI, 
VAP, and SSI). A study spanning 6 years of medical data in the National Nosocomial Infections 
Surveillance (NNIS) showed that out of 93,327 patients the most common of these four HAI 
classifications were VAPs and CAUTIs at 30.8% and 30.4%, respectively (Kupronis, Edwards, 
Horan, Richards, & Tokars, 2004). Bloodstream infections occurred at 11.9%, lower respiratory 
infections at 6.6%, surgical site infections at 4.4%, and central nervous system infections at 4.3% 
(Kupronis, Edwards, Horan, Richards, & Tokars, 2004). Another study confirmed this and found 
that in patients who had had an aneurysmal subarachnoid hemorrhage, CAUTIs were the most 
common HAIs (23.9%) (Dasenbrock, et al., 2016). This was followed by VAPs (23.0%), 
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meningitis/ventriculitis (4.4%), and CLABSIs (1.0%) (Dasenbrock, et al., 2016). A study from 
Germany showed that the overall incidence of HAIs in the neurosurgical ICU was 20.7 per 100 
(Dettenkofer, et al., 1999). The breakdown of this study is also similar to the afore mentioned 
studies done in the U.S. Pneumonia and urinary tract infections had the highest incidence of 9 per 
100 and 7.3 per 100, respectively (Dettenkofer, et al., 1999). Following those were bloodstream 
infections (1 per 100), urinary tract infections (7.3 per 100), meningitis (1.1 per 100), and others, 
which contained SSIs, catheter related local infection, bronchitis, and diarrhea grouped into the 
same category, (1.7 per 100) (Dettenkofer, et al., 1999). Similarly, the largest study on HAIs in 
Europe studied prevalence in 10,038 patients (Celik, 2004). 20.6% of the patients had a HAIs; of 
these HAIs, 46.9% was pneumonia, 17.8% were lower respiratory tract infections, 17.6% were 
urinary tract infections, and 12% were bloodstream infections (Celik, 2004). Another prospective 
study in Italy found that 32.6% of HAIs were VAPs, 9.1% were CLABSIs, 22.7% were CAUTIs, 
and 6.8% were SSIs (Orsi, et al., 2006). 
The CDC also has particular diseases and organisms it monitors because of their severity 
or their association with being spread primarily in a healthcare setting. These include 
Acinetobacter, Burkholderia cepacia, Candida auris, Clostridium difficile (C. difficile), 
Clostridium sordellii, carbapenem-resistant Enterobacteriaceae, gram-negative bacteria, hepatitis, 
HIV/AIDS, influenza, Klebsiella, methicillin-resistant Staphylococcus aureus (MRSA), 
Mycobacterium abscessus, norovirus, Pseudomonas aeruginosa (P. aeruginosa), Staphylococcus 
aureus (S. aureus), tuberculosis, vancomycin-intermediate and vancomycin-resistant 
Staphylococcus aureus (VRSA), and vancomycin-resistant Enterococci (Centers for Disease 
Control and Prevention, 2019). The most commonly seen disease-causing organisms according to 
the CDC’s multi-state study on HAIs are C. difficile (12.1%), S. aureus and MRSA (10.7%), 
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Klebsiella family organisms (10.3%), Escherichia coli (E. coli) (93.3%), organisms from the 
Enterococci family (8.7%), and organisms from the P. aeruginosa (7.1%) (Magill, et al., 2014). 
The NHSN focuses specifically on MRSA and C. difficile and their relevance in contributing to 
HAIs. In the most recent NHSN report, approximately 8,000 hospital-onset MRSA events and 
approximately 82,000 hospital-onset C. difficile events were reported. Comparisons between SIRs 
in the national data for acute care hospitals in 2017 and the national baseline for acute care 
hospitals in 2016 indicated a 14% decrease in MRSA and a 20% decrease in C. difficile, both of 
which were significant. Pennsylvania’s data for acute care hospitals in 2017 when compared to the 
national baseline for acute care hospitals in 2017 showed a 22% decrease in MRSA and a 18% 
decrease in C. difficile. Only the decrease in C. difficile-related HAIs was significantly lower in 
2017 when compared to Pennsylvania’s results in 2016; the decrease in MRSA was not significant.  
In particular, SSIs that are most common in neurosurgery ICUs include S. aureus, coagulase-
negative Staphylococci (CNS), P. aeruginosa, Klebsiella pneumoniae (K. pneumoniae), and other 
gram-positive bacteria (Orsi, et al., 2006). Meningitis infections which are associated with EVDs 
are S. aureus, Staphylococci, Enterococcus faecalis, P. aeruginosa, K. pneumoniae, and other 
gram-positive bacteria (Orsi, et al., 2006). According to another study, ventriculostomy-associated 
infections are often caused by S. epidermidis, Candida, and both gram-negative and gram-positive 
bacteria (Abulhasan, et al., 2018). Moreover, yet another study concluded that CNS, Streptococci, 
Corynebacterium spp., and herpesvirus are also associated with meningitis and ventriculitis in 
neurosurgery ICUs (Dettenkofer, et al., 1999). 
While SSIs are generally the least prevalent HAIs, they cause the most economic burden 
and more severely increase the morbidity and mortality in healthcare settings. Neurosurgical 
associated HAIs include SSIs (superficial or deep) after cranial or spinal surgery as well as surgical 
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meningitis and ventriculitis associated with EVD or shunt-related infection. Patients in the 
neurosurgical ICUs come with their own distinctive array of issues which further increase the 
morbidity of any contracted SSIs. There are many associated risk factors, both patient-related and 
procedure-related, that can increase the incidence of meningitis or ventriculitis as a result of SSIs. 
Commonly found patient-related risk factors include male sex, age of 70 or higher, non-trauma 
related procedure, and a higher American Society of Anesthesiologists (ASA) score. Procedure-
related factors often include an emergency procedure, the lack of antimicrobial prophylaxis, longer 
duration of the procedure, leakage of CSF after the procedure, and an early reoperation (Chiang, 
et al., 2014). A prospective cross-sectional study demonstrated that presence of SSIs were strongly 
associated with a longer total length of stay at a hospital, a higher body mass index, a longer 
surgical procedure, and the presence of a blood transfusion using bivariate analysis (Bellusse, 
Riberio, de Campos, de Brito Poveda, & Galvao, 2015). A larger retrospective study found that 
older patients, male sex, longer operation preparation time and operation duration, greater number 
of devices or insertions into and out of the body, and presence of multiple HAIs were all 
contributing factors to increased SSIs (Lee, et al., 2018). Another study focusing more specifically 
on SSIs related to craniotomies and craniectomies found the following bivariate associations: 
comorbidity of peripheral vascular diseases, prior operations or radiation on the brain, presence of 
a tumor, high glucose levels, an increased preoperative length of stay, an NHSN risk index score 
greater than or equal to 2, presence of any kind of CSF drain, and postoperative leakage of CSF 
(Chiang, et al., 2014). The study also found that increased duration of any operative procedure was 
significant in a multivariate model (Chiang, et al., 2014). Dasenbrock, et al. (2016) found that after 
an aneurysmal subarachnoid hemorrhage (SAH), the SAH severity scale and the number of non-
infectious complications were both significant in predicting the presence of meningitis or 
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ventriculitis. A prospective study which looked at deep neurosurgical wound infections leading to 
meningitis and ventriculitis after craniotomies found that using univariate analysis a Glasgow 
Coma Score less than 10, an emergency surgery, total shaving of the head, the use of an external 
drainage device, subsequent operation, and CSF leakage all increased the associated relative risk 
of infection significantly (Korinek, et al., 1997). Our focus here is EVD-related infections and 
preventative efforts. 
1.3 External Ventricular Drains 
External ventricular drain (EVD) placements are procedures commonly performed by 
neurosurgeons to relieve increased intracranial pressure (ICP) by draining CSF. They can be 
placed emergently at the bedside or electively in the operating room. Ventriculoperitoneal (VP) 
shunts drain the excess CSF fluid into a patient’s peritoneal cavity, whereas an EVD carries the 
excess CSF fluid out of the body and into a separate collection bag (Muralidharan, 2015). The 
amount of CSF drained from the EVD can be adjusted to maintain a constant and safe pressure on 
the brain. VP shunts are a long-term solution for increased ICP, whereas EVDs are typically used 
in the short-term. If there is continued need for shunting, the patient will undergo EVD removal 
and VP shunt placement. Estimates for incidence of meningitis and ventriculitis after placement 
of an EVD vary greatly and can be as little as 1 to 4% or can occur in up to 22% of cases (Parks 
& Nohra, 2010) (Tavakoli, Peitz, Ares, Hafeez, & Grandhi, 2017). Meningitis is defined as 
inflammation and infection of the meninges, while ventriculitis is defined as inflammation and 
infection of the ventricles. CSF can be drawn from the EVD directly or can be collected from the 
drainage bag to for testing and running cultures. Medications can also be introduced directly into 
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the subarachnoid space of the brain through the EVD. Once an EVD is in place, monitoring the 
patient and the drain for CSF leakage, fluctuating intracranial pressure, and obstruction in the 
tubing, device, or CSF fluid is vital to keeping the EVD safe and functional (Muralidharan, 2015). 
Meningitis and ventriculitis are often caused specifically by SSIs that are introduced during 
placement of the EVD or because of substandard EVD monitoring and care. Typical symptoms of 
meningitis and ventriculitis caused by SSIs in EVDs can be a new headache, nausea, lethargy, a 
change in mental state, and/ or a fever (Tunkel, et al., 2017). Once an infection is suspected, the 
CSF is tested for any abnormalities. Changes in CSF cell count, glucose, and/or protein might 
suggest presence of healthcare-associated meningitis or ventriculitis, but it does not guarantee it 
(Tunkel, et al., 2017). On the other hand, a normal CSF cell count, normal glucose, normal protein, 
and/or a negative gram stain does not necessarily exclude presence of healthcare-associated 
meningitis or ventriculitis (Tunkel, et al., 2017). Instead, a CSF culture is the definitive method of 
knowing whether a patient has contracted an HAI. If the culture test initially comes back as 
negative, it should be held for at least 10 days to ensure nothing grows in it (Tunkel, et al., 2017). 
A positive CSF culture, either single or multiple is strongly indicative of meningitis or ventriculitis, 
especially with clinical symptoms and abnormal cell counts (Tunkel, et al., 2017). However, an 
EVD, once removed, should not be cultured to determine presence of an HAI (Tunkel, et al., 2017). 
Associated risk factors that are specific to EVDs occurring are systemic infections 
introduced to the body externally, depressed skull fractures, lack of tunneling of EVD catheters, 
CSF leakage at the site of drain insertion, unsterile catheter irrigation, frequency of CSF sampling, 
and extensive duration of EVD placement (Muralidharan, 2015). Minimizing breaks in the EVD 
system by limiting the changing of collection bags and tubing will help to reduce pathogen 
colonization and possible CSF infection. In case of colonization, antibiotics can be introduced but 
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it is more likely that the entire EVD system will have to be replaced with another EVD 
(Muralidharan, 2015). EVDs can also suffer from mechanical malfunctions such as kinking in the 
tubes, a failure of any part of the drainage system, or migration of the EVD catheter (Muralidharan, 
2015). Other obstructions that can occur resulting in blocked EVDs and a possible infection are 
too much drainage of CSF, tight ventricles, or CSF leaks (Muralidharan, 2015). A review article 
on EVDs summarized the following variables as significantly increasing the chances of contracting 
an EVD infection based on univariate analysis: duration of catheterization, a neurosurgical 
operation, an already present co-infection, the use of multiple catheters simultaneously, age, and 
an underlying disease or a more severe diagnosis (Sorinola, Buki, Sandor, & Czeiter, 2019). 
1.4 Infection Prevention 
Evidence-based guidelines were issued to decrease the incidence of EVD-related 
infections. With counsel from the Healthcare Infection Control Practices Advisory Committee 
(HICPAC), the CDC and U.S. Department of Health and Human Services (DHHS) have 
established guidelines and strategies to prevent the spread of HAIs and to assist in surveilling the 
spread of HAIs in healthcare institutions (Healthcare Infection Control Practices Advisory 
Committee, 2017). These include guidelines specific to healthcare settings (e.g., inpatient and 
outpatient settings, dialysis), healthcare worker, disease or organism, procedure or device, 
antibiotic resistant organisms, and basic infection preventions (e.g., hand hygiene, disinfection and 
sterilization) (Healthcare Infection Control Practices Advisory Committee, 2017). In addition to 
these specific guidelines, there are also core guidelines that the HICPAC considers most vital to 
infection prevention and are unlikely to change regardless of any additional research conducted. 
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Of the published situation-specific categorized guidelines, the core guidelines selected are based 
on which recommendations were included in more than one of the numerous guidelines (Appendix 
A). Core practice categories that the HICPAC has outlined are leadership support, which refers to 
the bodies in charge of healthcare facilities and organizations; education and training of healthcare 
personnel on infection prevention; patient, family, and caregiver education; performance 
monitoring and feedback; standard precautions (i.e., hand hygiene, environmental cleaning and 
disinfection, injection and medication safety, risk assessment with appropriate use of personal 
protective equipment, minimizing potential exposures, reprocessing of reusable medical 
equipment); transmission-based precautions, temporary invasive medical devices for clinical 
management; and occupational health (Healthcare Infection Control Practices Advisory 
Committee, 2017). 
The Infections Diseases Society of America’s Standards and Practice Guidelines 
Committee in collaboration with the American Academy of Neurology, American Association of 
Neurological Surgeons, and Neurocritical Care Society have developed guidelines and 
recommendations for clinicians for the evaluation, diagnosis, and management of meningitis and 
healthcare-associated ventriculitis (Tunkel, et al., 2017). It provides the following guidelines for 
the best approach to prevent infection in patients with EVDs: 
• Administration of a prophylactic antimicrobial prior to placement of the EVD 
(Tunkel, et al., 2017) 
• Use of drains that are impregnated with antimicrobials (Tunkel, et al., 2017) 
• Opposition against prolonged administration of prophylactic antimicrobials for the 
entire duration of the EVD (Tunkel, et al., 2017) 
• Discouragement of fixed interval exchanges (Tunkel, et al., 2017) 
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• Implementation of a standardized protocol to insert CSF drains (Tunkel, et al., 
2017) 
Unfortunately, a six-year study conducted from 2006 to 2012 showed that the trends in 
mortality and length of stay related to bloodstream infections, pneumonia, SSIs, and UTIs has not 
changed substantially, indicating that Medicare’s introduction of the HACs Initiative has not been 
as successful as originally expected (Glied, Cohen, Liu, Neidell, & Larson, 2016). In order to 
further decrease the incidence of HAIs and associated their burden on the health system and 
patients, the U.S. Department of Health and Human Services (HHS) has included HAIs in their 
Healthy People 2020 goals. (Office of Disease Prevention and Health Promotion, 2019). Healthy 
People 2020 is a 10-year agenda implemented by the HHS to improve health in the United States 
by focusing on high priority issues (Office of Disease Prevention and Health Promotion, 2019). 
By partnering with the CDC, National Institute of Health (NIH), Food and Drug Administration 
(FDA), and others, a four-step plan was designed (Office of Disease Prevention and Health 
Promotion, 2019). They cover goals focused on decreasing HAIs at healthcare locations, 
specifically acute-care hospitals, ambulatory surgical centers, and end-stage renal disease 
facilities; increasing influenza vaccination among healthcare personnel, such as doctors, nurses, 
etc.; and promoting antibiotic stewardship (Office of Disease Prevention and Health Promotion, 
2019). 
1.5 Policy Change 
In July of 2017, our institution updated its policy regarding the care of ICP monitoring 
devices, which includes EVDs and their associated bedside care. The purpose of this policy change 
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was to reduce the incidence of HAIs for patients who had received EVDs because of the distinct 
compromising dangers that neurosurgical infections can have. The policy states the following: “All 
patients with an intracranial pressure device will be cared for by a registered professional nurse, 
who has been oriented to intracranial pressure monitoring and external ventricular drain 
management. A nurse to nurse consultation will be requested and provided by an experienced 
critical care unit nurse from medical intensive care unit, trauma burn center, or resource intensive 
care whenever necessary”. The policy also goes on to cover external drainage and monitoring 
system set up for an EVD for registered nurses; procedure for insertion of EVDs for physicians, 
advanced practice providers, and registered nurses; procedure for an ordered, soiled, or dislodged 
dressing change for physicians and advanced practice providers; procedure for obtaining cerebral 
perfusion pressure readings for registered nurses; procedure for CSF sample from an EVD for 
registered nurses; procedure for instillation into a proximal port of external drainage and 
monitoring system for physicians and advanced practice providers; procedure for changing of CSF 
collection bags for registered nurses; and important general aspects about external drainage and 
monitoring systems that should be taken into account. In addition to the update, the institution also 
held an educational workshop for registered nurses on proper EVD procedures and to familiarize 
them with the policy update, specifically highlighting the changes, in September 2017. The entire 
policy is included in Appendix B. 
1.5.1  Major Updates to Policy 
There were four major changes to the original policy that were expected to directly decrease 
the incidence and associated complications related to HAIs. The first change was implementing 
dressing changes after being soiled or upon order by a physician or advanced practice practitioner, 
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instead of the prior policy which stipulated stapling the dressing to the wound after insertion or 
removal of an EVD. The second change was regarding CSF collection for testing. Under the 
previous policy, the CSF drainage bag was collected every day and sent to the lab for testing, 
which meant that it took approximately twenty-four hours for the fluid to be tested and cultured. 
After implementation of the new policy, CSF was collected from the buretrol instead of the 
drainage bag and sent to the lab vials, shortening the processing time. The third policy change was 
the required use of five barriers (i.e., mask, cap, gloves, sterile gown, and sterile drape on the 
patient) were added to the already required hand hygiene and sterile technique for whenever a 
physician or advanced practice provider performs interventions that break the EVD system, such 
as inserting a new EVD or for repairing the system. The fourth and final change was that the 
frequency of CSF testing was changed from daily to two times a week on Mondays and Thursdays. 
All four of these changes to the policy were implemented in order to decrease the amount of breaks 
in the system and to ensure sterile techniques are used by all personnel who interact with EVD 
patients. 
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2.0 Methods 
2.1 Patient Sample Selection 
There were several steps involved in choosing the correct patient population to sample. 
Working in conjunction with the insurance department, patients with International Classification 
of Diseases, Tenth Revision, Clinical Modification (ICD) codes corresponding to “drainage of 
cerebral ventricle with drainage device” were isolated. Because UPMC slowly transitioned from 
ICD-9 to ICD-10 between August 2015 and November 2015 through the collection process, both 
0221 (from ICD-9) and 009630Z (from ICD-10) were used to choose patients who had undergone 
procedures for EVDs. Therefore, in September 2015 there was an overlap of ICD codes so that 
both ICD-9 and ICD-10 codes were used. From the pool of patients in the entire system who had 
at one point received an EVD, patients that had been admitted specifically for “neurosurgical” 
services were chosen. These selected patients’ electronic medical records on Cerner, specifically 
the surgical notes, pre-op and post-op notes, intraoperative notes, and follow-up evaluation notes, 
were carefully read to determine whether the patient had in fact received an EVD. The timeline 
for data collection was between January 2014 and October 2018. The policy update regarding 
intracranial pressure monitoring devices happened in July 2017, so patient cases that were dated 
before and including July 31, 2017 were classified as following the previous protocol whereas 
patient cases dated after July 31, 2017 were classified as following the new protocol. 
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2.2 Data Collection on Patients 
On the electronic medical record Cerner, the following were provided from the insurance 
department: medical record number, case number, procedure date, procedure time, procedure 
description, service used, and surgeon. Using the medical record number, each patient was 
confirmed to have had an EVD. Each patient’s CSF results were also recorded, specifically the 
highest white blood cell count, lowest glucose, highest protein, and highest red blood cell count. 
Any microbiology lab results for each patient’s CSF was recorded and the strain of a positive 
culture, if any, was noted. The site of the CSF sample collection was recorded as well. This referred 
to whether the CSF sample which was sent for testing was removed from the EVD collection bag 
or from the EVD’s buretrol. The duration of the EVD and the EVD placement type were also 
recorded. The EVD placement type referred to whether the patients received an EVD during a 
surgical procedure in an operating room (i.e., surgical) or whether the patient had an EVD placed 
at the bedside in the patient’s room (i.e., bedside). Patients were divided into three classes of HAIs: 
confirmed, possible, and no evidence. Patients with confirmed HAIs had microbiology lab results 
of CSF that indicated growth of an organism or organisms. Possible HAIs meant that the patient’s 
CSF had either a glucose level < 40 and/or a white blood cell count > 100. Patients with no 
evidence of HAIs had no microbiological growth in their CSF fluid and also had a glucose count 
greater than 40 and a white blood cell count fewer than 100.  
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2.3 Statistical Analysis 
The statistical analysis program STATA was used to analyze data. Simple linear regression 
modeling was used to determine how the duration of the EVD in days and procedure time in 
minutes affected the white blood cell count and glucose level with significance given at a p-value 
of < 0.05. Analysis of variance (ANOVA) modeling was used to determine whether the surgeon, 
location of CSF specimen sampling (i.e., bag or EVD), and EVD placement (i.e., bedside, surgical, 
or both) had an effect on white blood cell count and glucose levels. Each variable was analyzed 
separately using one-way ANOVA additive model and then analyzed again using an interaction 
model to determine whether they had any effect on each other. In order to model the continuous 
variables and discrete categorical variables together, analysis of covariance (ANCOVA) was used 
to determine interactions between EVD duration, procedure time, surgeon, specimen source, and 
EVD placement result together in a multivariable regression system. Multivariate analysis of 
variance (MANOVA) was used to determine how interactions between EVD duration, procedure 
time, surgeon, CSF specimen source, and EVD placement related to the white blood cell count and 
the glucose levels in the CSF. Logistic regression was used to determine the odds ratios of surgeon, 
CSF specimen source, and EVD placement on the presence of HAIs, as determined by CSF culture 
and white blood cell count and glucose level. The possible and confirmed HAIs were grouped 
together for the odds ratio analysis. Statistical significance for ANOVA, ANCOVA, MANOVA, 
and logistic regression was determined based on a p-value < 0.05. On significant variables 
determined by ANOVA, ANCOVA, and MANOVA regression analyses, postestimation pairwise 
tests were run using Scheffé’s correction. 
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3.0 Results 
There were 313 entries isolated from using both ICD-9 and ICD-10 codes 0221 and 
009630Z, respectively. There were 162 cases which used were specifically admitted for 
neurosurgical services and the focus of the analysis. After removing repeat cases (56) for patients 
who had multiple procedures on the same day, there were 106 unique patient cases. There were 36 
entries which had no CSF data and were assumed to have had no evidence of an HAI to require a 
CSF test. One of those entries with no CSF data had to be removed because the patient died before 
receiving an EVD. 28 of the entries with no CSF data were pre-policy, and 7 of the entries were 
post-policy. 70 entries had their CSF fluid tested, of which 7 entries had confirmed HAIs based on 
the microbiology culture and 63 entries had no growth in their CSF. 5 of the entries with confirmed 
HAIs were pre-policy, and 2 of them were post-policy. Of the 63 entries which had no growth in 
the CSF culture, 37 of them had possible HAIs based on their glucose or white blood cell count; 
31 entries were pre-policy, and 6 entries were post-policy. The remaining 26 entries without 
growth in the CSF culture had no evidence of HAIs because of their normal glucose and white 
blood cell count; 21 were pre-policy, and 5 were post-policy. These results are summarized in 
Table 1. 
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Figure 1 Flowchart of Patient Data 
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code
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Services"
106 unique entries
70 entries with CSF 
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evidence of HAIs
21 pre-policy entries
5 post-policy entries
7 entries with 
confirmed HAIs
5 pre-policy entries
2 post-policy entries
36 entries with no 
CSF data
7 post-policy entries28 pre-policy entries
1 entry removed; 
patient died before 
EVD inserted
56 repeat entries 
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Table 1 Summary of Patient and EVD Procedures 
 Pre-Policy Cases Post-Policy Cases 
Confirmed HAIs 5 2 
Possible HAIs 31 6 
No Evidence of HAIs (CSF 
Tested) 
21 5 
No Evidence of HAIs (No 
CSF Tested) 
28 7 
 
Table 2 categorizes and summarizes characteristics for the 106 unique entries. 67 entries 
(69.07%) had an EVD placed during surgery, 27 entries (27.84%) had a bedside EVD, 3 entries 
(2.83%) had both, and 9 entries (8.49%) did not explicitly mention whether the EVD was placed 
surgically or by the bedside. 36 entries (33.96%) did not have CSF taken for analysis. 58 entries 
(54.72%) had CSF taken from the EVD drainage bag while 12 entries (11.32%) had CSF taken 
from the buretrol. Surgeon 1 performed 5 procedures (4.72%), surgeon 2 performed 55 procedures 
(51.89%), surgeon 3 performed 11 procedures (10.38%), surgeon 4 performed 21 procedures 
(19.81%), surgeon 5 performed 10 procedures (9.43%), and surgeons 6, 7, 8, and 9 performed 1 
procedure each (0.94%). 14 entries (13.21%) did not have EVD monitoring, so the duration of the 
EVD could not be determined. The average duration of the EVD in days was 7.98 ± 5.35. The 
average procedure time in minutes was 144.83 ± 124.23. 
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Table 2 Patient Characteristics 
Variable Entries 
EVD Placement 
Surgery 67 (63.21%) 
Bedside 27 (25.47%) 
Both 3 (2.83%) 
Unknown 9 (8.49%) 
Specimen From 
No CSF 36 (33.96%) 
EVD Bag 58 (54.72%) 
EVD Buretrol 12 (11.32%) 
Surgeon 
1 5 (4.72%) 
2 55 (51.89%) 
3 11 (10.38%) 
4 21 (19.81%) 
5 10 (9.43%) 
6 1 (0.94%) 
7 1 (0.94%) 
8 1 (0.94%) 
9 1 (0.94%) 
EVD Duration 
No Data Monitoring 14  
Mean (days) 7.98 ± 5.35 
Procedure Time 
Mean (minutes) 144.83 ± 124.23 
 
Table 3 focused specifically on the patients’ white blood cell count and possible variables 
that could have affected it. Simple linear regression analysis on procedure time (p-value 0.363), 
EVD duration (0.622), and procedure time when controlling for EVD duration (p-value 0.362), 
and EVD duration controlling for procedure time (p-value 0.621) showed that there was no 
significant effect on the outcome. ANOVA regression analysis was conducted on the categorical 
variables. The following variables did not significantly affect the white blood cell count separately: 
HAI presence (p-value 0.292), surgeon (p-value 0.415), CSF specimen source (p-value 0.599), and 
EVD placement (p-value 0.737). An additive model of the surgeon, CSF specimen source, and 
EVD placement showed no significant effect on the white blood cell count. On the other hand, an 
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interactive model of the surgeon, CSF specimen source, and EVD placement did have a significant 
effect on the white blood cell count (p-value 0.020). When this model was broken down, the 
surgeon and CSF specimen source while controlling for EVD placement was significantly related 
to the white blood cell count (p-value 0.020); additionally, the surgeon and EVD placement when 
controlling for the CSF specimen source was also significantly related to the white blood cell count 
(p-value 0.003). Regression models taken both the categorical variables (surgeon, CSF specimen 
source, and EVD placement) and continuous variables (procedure time and EVD duration) into 
account showed no significance in the additive model (p-value 0.585) but was significant in the 
interactive model (p-value < 0.001). Breaking the interactive model down further showed that 
significant relationships exited between the following and the white blood cell count: surgeon 
controlling for everything else (p-value < 0.001), surgeon and CSF specimen source controlling 
for everything else (p-value < 0.001), EVD placement controlling for everything else (p-value 
0.021), surgeon and EVD placement controlling for everything else (p-value < 0.001), surgeon and 
procedure time controlling for everything else (p-value < 0.001), surgeon and EVD duration 
controlling for everything else (p-value 0.031), and EVD duration controlling for everything else 
(p-value < 0.001). Only the significant models were further analyzed and documented. 
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Table 3 White Blood Cell Count’s Relation to Variables using Regression Analyses 
Variables p-value 
Simple Linear Regression Analysis 
Procedure Time 0.363 
EVD Duration 0.622 
Procedure Time controlling for EVD Duration 0.362 
EVD Duration controlling for Procedure Time 0.621 
ANOVA Regression Analysis 
HAI Presence 0.292 
Surgeon 0.415 
CSF Specimen Source 0.599 
EVD Placement 0.737 
Surgeon, CSF Specimen Source, EVD Placement (Additive) 0.474 
Surgeon, CSF Specimen Source, EVD Placement (Interactive) 0.020 
          Surgeon and CSF Specimen Source controlling for EVD Placement 0.002 
          Surgeon and EVD Placement controlling for CSF Specimen Source 0.003 
ANCOVA Regression Analysis 
Surgeon, CSF Specimen Source, EVD Placement, Procedure Time, EVD 
Duration (Additive) 
0.585 
Surgeon, CSF Specimen Source, EVD Placement, Procedure Time, EVD 
Duration (Interactive) 
< 0.001 
          Surgeon controlling for everything else < 0.001 
          Surgeon and CSF Specimen Source controlling for everything else < 0.001 
          EVD Placement controlling for everything else 0.021 
          Surgeon and EVD Placement controlling for everything else < 0.001 
          Surgeon and Procedure Time controlling for everything else < 0.001 
          Surgeon and EVD Duration controlling for everything else < 0.001 
          Procedure Time and EVD Duration controlling for everything else 0.031 
          EVD Duration controlling for everything else < 0.001 
 
Table 4 focused on specially on the patients’ glucose levels and the possible variables that 
could have affected it. Neither the procedure time (p-value 0.238) nor the EVD duration (0.852) 
affected the glucose levels. Moreover, procedure time controlling for EVD duration (p-value 
0.238) and EVD duration controlling for procedure time (p-value 0.853) did not have any 
significant effect on glucose levels either. The presence of HAIs was very significantly correlated 
to the glucose level (p-value 0.001). ANOVA analysis of the other variables, including surgeon 
(0.714), CSF specimen source (0.373), and EVD placement (0.459), did not yield significant 
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results. Both the additive model and the interactive model looking at the surgeon, CSF specimen 
source, and EVD placement were not significantly related to glucose levels (P-value 0.682 and 
0.576, respectively). The additive model and interactive model using the ANCOVA regression 
analysis on all five variables (surgeon, CSF specimen source, EVD placement, procedure time, 
and EVD duration) also did not show any significant relation to the glucose levels (p-value 0.799 
and 0.769, respectively). 
Table 4 Glucose Level’s Relation to Variables using Regression Analyses 
Variable p-value 
Simple Regression Analysis 
Procedure Time 0.238 
EVD Duration 0.852 
Procedure Time controlling for EVD Duration 0.238 
EVD Duration controlling for Procedure Time 0.853 
ANOVA Regression Analysis 
HAI Presence 0.001 
Surgeon 0.714 
CSF Specimen Source 0.373 
EVD Placement 0.459 
Surgeon, CSF Specimen Source, EVD Placement (Additive) 0.682 
Surgeon, CSF Specimen Source, EVD Placement (Interactive) 0.576 
ANCOVA Regression Analysis 
Surgeon, CSF Specimen Source, EVD Placement, Procedure Time, EVD 
Duration (Additive) 
0.799 
Surgeon, CSF Specimen Source, EVD Placement, Procedure Time, EVD 
Duration (Interactive) 
0.769 
 
MANOVA regression analysis determined that there was so significant relation of the 
surgeon, CSF specimen source, EVD placement, procedure time, and EVD duration variables to 
both the white blood cell count and the glucose levels. Wilk’s lambda test statistic had a p-value 
of 0.798, Lawley-Hotelling trace test statistic had a p-value of 0.812, Pillai’s trace test statistic had 
a p-value of 0.783, and Roy’s largest root test statistic had a p-value of 0.577. 
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Table 5 MANOVA Analysis of White Blood Cell Count and Glucose Level to All Variables 
Variables Wilks’s 
Lambda 
Lawley-
Hotelling 
Trace 
Pillai’s 
Trace 
Roy’s 
Largest Root 
Surgeon, CSF Specimen 
Source, EVD Placement, 
Procedure Time, EVD 
Duration 
0.798 0.812 0.783 0.577 
 
Testing means from ANOVA using pairwise comparison yielded the results from Table 6. 
The white blood cell ANOVA test for the surgeon and CSF specimen source interaction while 
controlling for EVD placement resulted in surgeon 5 and an EVD bag for the CSF specimen source 
compared to surgeon 2 and an EVD bag for the CSF specimen source was significant (p-value 
0.44) with a contrast of 16787.13 ± 7340.216. The white blood cell ANOVA test for the surgeon 
and EVD placement interaction while controlling for CSF specimen source resulted in surgeon 5 
and a surgical placement compared to surgeon 2 and a surgical placement was significant (p-value 
0.11) with a contrast of 24684.16 ± 5991.203. The glucose ANOVA test for HAI presence showed 
a significant relationship when comparing the possible HAI entries to the entries which had no 
evidence of HAIs (p-value 0.001) with a contrast of -19.04 ± 5.631. The remaining comparisons 
displayed as “Not Estimable” in STATA. 
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Table 6 Pairwise Comparisons of Significant Variables for White Blood Cell Count and Glucose Levels 
Variables Contrast p-value 
White Blood Cell ANOVA 
Surgeon and CSF Specimen 
Source interaction controlling 
for EVD Placement 
Surgeon 5 and EVD Bag vs. 
Surgeon 2 and EVD Bag 
(16787.13 ± 7340.216) 
0.044 
Surgeon and EVD Placement 
interaction controlling for 
CSF Specimen Source 
Surgeon 5 and Surgical 
Placement vs. Surgeon 2 and 
Surgical Placement 
(24684.16 ± 5991.203) 
0.011 
Glucose Count ANOVA 
HAI Presence HAI Possible vs. No Evidence 
of HAI 
(-19.04 ± 5.631) 
0.001 
 
The odds ratio of each variable on the presence of HAIs was also determined as showed in 
Table 7. For this logistic regression analysis, the possible and confirmed HAI entries were grouped 
together and were compared to the entries that had to evidence of HAIs. The odds ratio of the 
procedure time on HAIs was 1.001 (95% CI 0.999, 1.005) with a p-value of 0.290. EVD duration 
was found to be significant in determining the presence of HAIs with a p-value of < 0.001 and an 
odds ratio of 1.202 (95% CI 1.080, 1.338). The odds ratio of the surgeon on HAI presence was 
1.047 (95% CI 0.803, 1.338) with a p-value of 0.735 and was not significant. CSF specimen source 
and EVD placement were both significantly related to HAI presence (p-value < 0.001 and 0.013, 
respectively) with odds ratios of 7.000 (CI 95% 2.888, 16.966) and 2.381 (95% CI 1.118, 5.074), 
respectively. When analyzing procedure time, EVD duration, surgeon, CSF specimen source, and 
EVD placement together in a joint odds ratio, the following outcomes were obtained when 
controlling for the other variables: procedure time had an odds ratio of 1.001 (95% CI 0.998, 1.005) 
and a p-value of 0.541, EVD duration had an odds ratio of 1.149 (95% CI 1.018, 1.300) and a p-
value of 0.025, surgeon had an odds ratio of 1.032 (95% CI 0.751, 1.418) and a p-value of 0.847, 
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CSF specimen source had an odds ratio of 4.233 (95% CI 1.685, 10.635) and a p-value of 0.002, 
and EVD placement had an odds ratio of 1.623 (95% CI 0.642, 4.101) and a p-value of 0.306. 
 
Table 7 Odds Ratios of Variables as Related to HAI Presence 
Variables Odds Ratios (95% CI) p-value 
Separate Analyses 
Procedure Time 1.001 (0.999, 1.005) 0.290 
EVD Duration 1.202 (1.080, 1.338) < 0.001 
Surgeon 1.047 (0.803, 1.366) 0.735 
CSF Specimen Source 7.000 (2.888, 16.966) < 0.001 
EVD Placement 2.381 (1.118, 5.074) 0.013 
Joint Analyses 
Procedure Time 1.001 (0.998, 1.005) 0.541 
EVD Duration 1.149 (1.018, 1.300) 0.025 
Surgeon 1.032 (0.751, 1.418) 0.847 
CSF Specimen Source 4.233 (1.685, 10.635) 0.002 
EVD Placement 1.623 (0.642, 4.101) 0.306 
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4.0 Discussion 
The factors chosen to determine possible risk association were based on recommendations 
from the CDC, guidelines from the Infectious Diseases Society of America (IDSA), and previously 
published research papers. Simple linear regression showed no significant impact of procedure 
time and EVD duration, both separately and together, on the white blood cell count or glucose 
levels. Since the white blood cell count and the glucose levels were used as a controlling factor for 
possible HAIs, the presence of increased white blood cells and a lower glucose was assumed to 
correlate with a possible infection. This was used in the many cases that a clear confirmed HAI 
was not verified by CSF culture. The results of these regression analyses disagreed with results 
that Lee, et al. (2018) and Korinek, et al. (1997) found, possibly because of the small sample size 
that was analyzed. It was unexpected because the longer the interior is exposed to the environment, 
the more likely it is to be exposed to infection-causing organisms. 
ANOVA regression analysis demonstrated a significant link between the surgeon, CSF 
specimen source, and EVD placement on the white blood cell count when using the interactive 
model (p-value 0.020). When this was broken down, the two significant categories were surgeon 
and CSF specimen source interactions controlling for EVD placement (p-value 0.002) and surgeon 
and EVD placement interactions when controlling for CSF specimen source (p-value 0.003). Using 
postestimation methods of pairwise comparison with Scheffé correction, the significant 
connections within the interactive ANOVA model were tested. The surgeon and CSF specimen 
source interaction while controlling for EVD placement showed that surgeon five and a CSF 
sample from the EVD bag compared pairwise to surgeon two and a CSF sample from the EVD 
bag was significant (p-value 0.044) with a contrast in white blood cell count of 16787.13 ± 
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7340.216. The surgeon and EVD placement interaction while controlling for the CSF specimen 
source showed that surgeon five and a surgically placed EVD compared pairwise to surgeon two 
and a surgically placed EVD was significant (p-value 0.011) with a contrast in white blood cell 
count of 24684.16 ± 5991.203. Both of these outcomes could be the result of an outlier that had a 
particularly high white blood cell count than is typically found in the case of an infection. 
Furthermore, it was unusual to see that the presence of HAIs did not affect the white blood cell 
count because high counts of white blood cells were one of the characteristics used to classify 
presence of a possible HAI. This unusual result could be explained by a left-skewed distribution 
instead of a normal distribution of white blood cells. For the glucose levels, the only ANOVA 
regression analysis with significant results was the presence of HAIs (p-value 0.001). Pairwise 
comparison with Scheffé correction showed that the contrast between glucose levels in patients 
with possible HAIs and patients with no evidence of HAIs was -19.04 ± 5.631, which was 
significant with a p-value of 0.001. This was logical since low glucose levels were used to establish 
which patients had possible HAIs. No comparable data was found in the literature for CSF source 
and EVD placement and requires further analysis to determine whether a significant difference 
exists between the two and their connection to incidence of HAIs. 
ANCOVA regression analysis established a significant link between the white blood cell 
count and an interactive model between the surgeon, CSF specimen source, EVD placement, 
procedure time, and EVD duration (p-value < 0.001). After breaking this regression model down, 
the following had significant interactions with the white blood cell count: surgeon controlling for 
everything else (p-value < 0.001), surgeon and CSF specimen source controlling for everything 
else (p-value < 0.001), EVD placement controlling for everything else (p-value 0.021), surgeon 
and EVD placement controlling for everything else (p-value < 0.001), surgeon and procedure time 
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controlling for everything else (p-value < 0.001), surgeon and EVD duration controlling for 
everything else (p-value < 0.001), procedure time and EVD duration controlling for everything 
else (p-value 0.031), and EVD duration controlling for everything else (p-value < 0.001). 
Postestimation analysis with this ANCOVA regression yielded results that were “Not Estimable”. 
Having taken every variable into account resulted in a model that was significantly affecting the 
white blood cell count; however, there is no way of indicating by how much and which specific 
variables were significant because of the lack of postestimation calculations. There was no 
significant relationship between the additive and interactive ANCOVA models for any of the 
variables and the glucose levels. MANOVA showed no significant interactions between surgeon, 
CSF specimen source, EVD placement, procedure time, and EVD duration with the white blood 
cell count and the glucose levels. 
The only significant variables when compared separately as they related to the presence of 
HAIs were EVD duration, which had an odds ratio of 1.001 (95% CI, 1.080, 1.338) and a p-value 
< 0.001, the CSF specimen source, which had an odds ratio of 7.000 (95% CI, 2.888, 16.966) and 
a p-value < 0.001, and the EVD placement, which had an odds ratio of 2.381 (95% CI, 1.118, 
5.074) and a p-value 0.013. When the variables were analyzed together, the significant odds ratios 
were EVD duration with a p-value of 0.025 (OR 1.149; 95% CI 1.018, 1.300) and CSF specimen 
source with a p-value of 0.002 (OR 4.233, 95% CI 1.685, 10.635). While the EVD placement and 
CSF specimen source were not variables that were studied in research, the increase in HAIs as a 
result of EVD duration is a well-documented occurrence. Though it follows that a sample which 
has been collecting in a bag for a longer period of time is more likely to have growth in CSF culture 
compared to the CSF specimen, it is also possible that the greater number of entries prior to the 
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switch which required CSF collection from the buretrol is a confounding variable, implying that 
the reduction in HAIs may not necessarily be a result of the CSF specimen source. 
The study is not without its limitations, the biggest one being that the study was a 
retrospective observational study. While a randomized control trial would be the most effective 
way to conduct the study, it cannot be conducted because of ethical reasons. Another limitation 
was that the number of patients was too small and attributed to the statistically inconclusive results. 
Because of how recent the policy change is, the number of patients after implementation of the 
policy is significantly fewer than the patients before policy implementation. Matching the cases to 
the controls and using pair-wise comparisons based on factors such as age, procedure description 
(e.g., craniotomy, hematoma evacuation), sex, or others could help to emphasize important factors. 
Even after trying to eliminate biases, there will still remain factors which have not been taken into 
account in determining causes or risk factors or the effect of the policy on HAI incidence. 
This study can be improved upon and expanded by including other factors in the analysis 
to determine whether they have any effect on the presence of HAIs, such as age, sex, and/ or other 
comorbidities. Since the policy is recent and the patient sample size too small, redoing the study 
after some time has passed to increase sample size will help to determine whether any factors are 
significantly affecting HAIs. This study can eventually be used to continue updating policies 
regarding HAIs related to EVDs. Patients who are likely to be at risk based on these results can be 
monitored more closely for potential incidents of HAIs or can be given more aggressive 
prophylactic measures. 
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Appendix A Core Infection Prevention and Control Practices for Safe Healthcare Delivery 
in All Settings Recommendations by the HICPAC 
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